Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.

Aminopyridines / chemistry Binding Sites Dopamine Agonists / chemical synthesis Energy Transfer HEK293 Cells Humans Luminescence Morpholines / chemistry Protein Binding Receptors, Dopamine D2 / chemistry Receptors, Dopamine D3 / chemistry Stereoisomerism Structure-Activity Relationship
biased agonism bitopic ligand chirality dopamine D2 receptor dopamine D3 receptor functional selectivity subtype affinity subtype selectivity

Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
13 04 2021
Historique:
received: 15 03 2021
revised: 06 04 2021
accepted: 09 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 21 9 2021
Statut: epublish

Résumé

The dopamine D2/D3 receptor (D

Identifiants

DOI: 10.3390/biom11040570 PMID: 33924613 PMC: PMC8069330
pubmed: 33924613
pii: biom11040570
doi: 10.3390/biom11040570
pmc: PMC8069330
pii:
doi:

Substances chimiques

Aminopyridines 0
Dopamine Agonists 0
Morpholines 0
PF 592379 0
Receptors, Dopamine D2 0
Receptors, Dopamine D3 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : Z1A DA000389
Pays : United States
Organisme : NIH HHS
ID : Z1A DA000606
Pays : United States

Références

J Pharmacol Exp Ther. 2011 Feb;336(2):296-302
pubmed: 21030484
J Med Chem. 2012 Aug 23;55(16):7141-53
pubmed: 22845053
Trends Endocrinol Metab. 2014 Nov;25(11):593-600
pubmed: 25190097
Curr Top Med Chem. 2015;15(10):908-26
pubmed: 25832718
J Med Chem. 2017 Apr 13;60(7):2890-2907
pubmed: 28300398
J Med Chem. 2017 Feb 23;60(4):1478-1494
pubmed: 28186762
CNS Drugs. 2021 Mar;35(3):253-264
pubmed: 33651366
Neurotox Res. 2013 Nov;24(4):523-31
pubmed: 23820985
Nature. 1990 Sep 13;347(6289):146-51
pubmed: 1975644
Biochem Biophys Res Commun. 2020 Jul 30;528(3):432-439
pubmed: 32505358
J Biol Chem. 2012 Mar 16;287(12):8864-78
pubmed: 22291025
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:609-628
pubmed: 33411583
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):E8178-E8186
pubmed: 27911814
Curr Top Med Chem. 2011;11(7):760-70
pubmed: 21291399
Nat Chem Biol. 2017 Aug 18;13(9):929-937
pubmed: 28820879
J Med Chem. 2017 Jan 26;60(2):580-593
pubmed: 27983845
J Med Chem. 2015 Jul 23;58(14):5361-80
pubmed: 25826710
ACS Med Chem Lett. 2020 Feb 28;11(10):1956-1964
pubmed: 33062179
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93
pubmed: 22025698
Neuropsychopharmacology. 2016 Feb;41(3):704-15
pubmed: 26129680
J Med Chem. 2016 Apr 14;59(7):2973-88
pubmed: 27035329
ACS Pharmacol Transl Sci. 2019 Feb 8;2(1):52-65
pubmed: 30775693
ACS Chem Neurosci. 2020 Oct 21;11(20):3309-3320
pubmed: 32969645
ACS Chem Biol. 2018 Apr 20;13(4):1038-1047
pubmed: 29485852
Mol Pharmacol. 2008 Jul;74(1):59-69
pubmed: 18424554
Mol Pharmacol. 2017 Jun;91(6):586-594
pubmed: 28265019
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
Cell Signal. 2018 Jan;41:75-81
pubmed: 28716664
Pharmacol Res. 2019 May;143:48-57
pubmed: 30844536
Biochem Pharmacol. 2018 Feb;148:315-328
pubmed: 29325769
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Cereb Cortex. 2017 Jan 1;27(1):435-446
pubmed: 26483399
CNS Neurol Disord Drug Targets. 2010 Nov;9(5):596-600
pubmed: 20632968
J Med Chem. 2019 Jul 11;62(13):6287-6314
pubmed: 31257877
J Neurochem. 2003 Nov;87(3):631-41
pubmed: 14535946
Science. 2010 Nov 19;330(6007):1091-5
pubmed: 21097933
ACS Chem Neurosci. 2017 Mar 15;8(3):486-500
pubmed: 27801563
J Med Chem. 2012 Aug 9;55(15):6689-99
pubmed: 22632094
Trends Pharmacol Sci. 2007 Aug;28(8):390-6
pubmed: 17629962
J Biol Chem. 2001 Aug 10;276(32):30308-14
pubmed: 11373283
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11271-5
pubmed: 7972046
J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
pubmed: 16803859
J Med Chem. 2016 Aug 25;59(16):7634-50
pubmed: 27508895
Mol Pharmacol. 2014 Jul;86(1):96-105
pubmed: 24755247
Ageing Res Rev. 2020 Jan;57:100994
pubmed: 31765822
Mol Pharmacol. 2013 Dec;84(6):854-64
pubmed: 24061855
Neuropharmacology. 2016 Jan;100:106-15
pubmed: 25896768
Ann N Y Acad Sci. 2010 Feb;1187:4-34
pubmed: 20201845
Nat Med. 2003 Jun;9(6):762-7
pubmed: 12740572
Eur Neuropsychopharmacol. 2015 Sep;25(9):1470-9
pubmed: 25453482
Nat Commun. 2016 Feb 24;7:10842
pubmed: 26905976
J Med Chem. 2020 Mar 12;63(5):1779-1797
pubmed: 31499001
Pharmacol Ther. 2016 Sep;165:164-77
pubmed: 27343365
J Clin Pharm Ther. 2018 Feb;43(1):1-7
pubmed: 29119585
J Med Chem. 2017 May 25;60(10):4126-4134
pubmed: 28140580
Pharmacol Rev. 1997 Sep;49(3):231-52
pubmed: 9311022

Auteurs

Pramisha Adhikari (P)

Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.

Bing Xie (B)

Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.

Ana Semeano (A)

Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA.

Alessandro Bonifazi (A)

Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.
ORCID: 0000-0002-7306-0114

Francisco O Battiti (FO)

Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.

Amy H Newman (AH)

Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.

Hideaki Yano (H)

Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.
Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA.

Lei Shi (L)

Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Aminopyridines › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents dopaminergiques › Agonistes de la dopamine › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Phénomènes chimiques › Transfert d'énergie › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Phénomènes physiques › Rayonnement › Rayonnement non ionisant › Lumière › Luminescence › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Oxazines › Morpholines › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur D2 de la dopamine › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur D2 de la dopamine › Récepteur D3 de la dopamine › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes de chimie organique › Isomérie › Stéréoisomérie › Chirality of Novel Bitopic Agonists Determines...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Chirality of Novel Bitopic Agonists Determines...